Merck & Co. stock is last at USD 147.97, down 0.01 percent in New York trading

{
  "signal_id": "5077d29d-073a-6ead-f569-071ef333791d",
  "signal_type": "news",
  "signal_subtype": "launches",
  "detected_at": "2026-09-25T16:39:59+00:00",
  "company": {
    "name": "Merck",
    "domain": "merck.com"
  },
  "data": {
    "url": "https://www.ad-hoc-news.de/boerse/news/nachboerse/merck-and-co-stock-is-last-at-usd-147-97-down-0-01-percent-in-new-york/70184783",
    "title": "Merck & Co. stock is last at USD 147.97, down 0.01 percent in New York trading - AD HOC NEWS",
    "excerpt": "Merck & Co. stock was last at USD 147.97 in New York trading at 12:39 p.m. ET on September 25, 2026, down USD 0.01 or 0.01 percent from USD 147.98. As Merck reported on September 25, 2026, the FDA approved Welireg plus Lenvima for certain previously treated renal-cell carcinoma patients. Merck traded 0.54 percentage points below the Nasdaq Composite, which was up 0.53 percent at 12:39 p.m. ET. Merck & Co., Inc. (ISIN US58933Y1055) opened at USD 148.06 in New York trading on September 25, 2026. Merck reached a session high of USD 149.94 and a session low of USD 147.48 during the session. Merck's intraday range was USD 2.46, and the last price stood USD 8.95 below the 52-week high of USD 156.92. Merck's volume was 2,743,836 shares at 12:39 p.m. ET against an average volume of 10,094,450 shares. Merck was last at USD 147.97 at 12:39 p.m. ET, leaving the shares between the session low and high. Merck's last price was USD 0.01 below the previous session level of USD 147.98. Merck's session movement therefore amounted to a decline of 0.01 percent at the stated time. Merck's European Tradegate quotation was EUR 129.64, down 0.34 percent at 10:47 a.m. CET on September 25, 2026. Merck's FDA approval covered adults with advanced renal-cell carcinoma after treatment with a PD-1 or PD-L1 inhibitor. The approval involved Welireg, Merck's belzutifan, and Lenvima, which was discovered by...",
    "product": "Welireg plus Lenvima",
    "summary": "Merck & Co. received FDA approval for its combination therapy of Welireg and Lenvima for certain previously treated renal-cell carcinoma patients.",
    "planning": false,
    "image_url": "https://mdb.ad-hoc-news.de/bild/bild-2671677_1920_1080.webp",
    "confidence": 0.9,
    "product_data": {
      "name": "Welireg plus Lenvima",
      "full_text": "Welireg plus Lenvima",
      "fuzzy_match": false
    },
    "product_tags": [
      "medical"
    ],
    "published_at": "2026-09-25T16:39:59Z",
    "effective_date": "2026-09-25",
    "article_sentence": "As Merck reported on September 25, 2026, the FDA approved Welireg plus Lenvima for certain previously treated renal-cell carcinoma patients.",
    "related_company_name": "Eisai",
    "related_company_domain": "eisai.com"
  }
}

curl https://signals.autobound.ai/v1/signals/5077d29d-073a-6ead-f569-071ef333791d \
  -H "X-API-KEY: $AUTOBOUND_API_KEY"

curl -X POST https://signals.autobound.ai/v1/companies/enrich \
  -H "X-API-KEY: $AUTOBOUND_API_KEY" \
  -H "Content-Type: application/json" \
  -d '{"domain":"merck.com","limit":20}'